

February 28, 2018

(Electronically Filed)
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P O Box 1450
Alexandria, VA 22313-1450

Inter Partes Review IPR2018-00717 (U.S. Patent No. 9,492,393)
Exhibit Cover Letter Per 37 C.F.R. § 42.6(e)(4)(ii)

Dear Patent Trial and Appeal Board:

This transmittal letter identifies Exhibits 1001-1068, being filed concurrently with the present Petition for *Inter Partes* Review. Pursuant to 37 C.F.R. § 42.6(e)(4)(ii), the Certificate of Service attached to the end of the Petition for *Inter Partes* Review filed herewith, incorporates Exhibits 1001-1068, as listed below:

Exhibit #	Reference
1001	U.S. Patent No. 9,492,393 (“the ’393 Patent”)
1002	U.S. Patent No. 1,479,293 (“the ’293 Patent”)
1003	Finding of Facts and Conclusion of Law, <i>Purdue Pharma L.P. et al. v. Amneal Pharmaceuticals LLC</i> , No. 13-cv-3372 (S.D.N.Y. Apr. 8, 2015) (“SDNY Decision”)
1004	U.S. Patent No. 8,337,888 (“the ’888 Patent”)
1005	Patent Owners’ Resp. to Petition for <i>Inter Partes</i> Review Under 35 U.S.C. § 313 and 37 C.F.R. § 42.107, <i>Amneal v. Purdue</i> , IPR2016-01027 (P.T.A.B. Feb. 8, 2017)
1006	U.S. Patent No. 9,060,976 (“the ’976 Patent”)
1007	Patent Owners’ Resp. to Petition for <i>Inter Partes</i> Review Under 35 U.S.C. § 313 and 37 C.F.R. § 42.107, <i>Amneal v. Purdue</i> IPR2016-01413 (P.T.A.B. Apr. 10, 2017)
1008	U.S. Patent No. 9,034,376
1009	Finding of Facts and Conclusion of Law, <i>Purdue Pharma L.P. et al. v. Teva Pharms. USA, Inc.</i> , No. 11-cv-2037, 11-cv-5083 (S.D.N.Y. Jan. 14, 2014) (“SDNY II”), <i>aff’d</i> , 2014-1306, -1307 (Fed. Cir. Feb. 1, 2016)
1010	U.S. Patent No. 8,114,383 (“the ’383 Patent”)
1011	Patrick Radden Keefe, <i>The Family that Built an Empire of Pain</i> , <i>The New Yorker</i> , Oct. 30, 2017
1012	Christopher Glazek, <i>The Secretive Family Making Billions from the Opioid Crisis</i> (Oct. 16, 2017), http://www.esquire.com/news-politics/a12775932/sackler-family-oxycotin/

Patent Trial and Appeal Board
U.S. Patent and Trademark Office
February 28, 2018
Page 2

Exhibit #	Reference
1013	Harriet Ryan <i>et al.</i> , ‘You want a description of hell?’ <i>OxyContin’s 12-Hour Problem</i> (May 5, 2016), http://www.latimes.com/projects/oxycontin-part1/
1014	Harriet Ryan <i>et al.</i> , <i>More than 1 million OxyContin pills ended up in the hands of criminals and addicts. What the drugmaker knew</i> (July 10, 2016), http://www.latimes.com/projects/la-me-oxycontin-part2/
1015	Harriet Ryan <i>et al.</i> , <i>OxyContin goes global — “We’re only just getting started”</i> (Dec. 18, 2016), http://www.latimes.com/projects/la-me-oxycontin-part3/
1016	U.S. Patent No. 5,508,042 (“Oshlack 1”)
1017	U.S. Patent Publication No. 2003/0068375 (“Wright”)
1018	Complaint, <i>Purdue Pharma L.P. et al. v. Amneal Pharmaceuticals, LLC</i> , No. 17-cv-00210 (D. Del. Mar. 1, 2017), ECF No. 1
1019	Declaration of Benjamin Oshlack (Exhibit 2097) in IPR2016-01027 and -01028
1020	Complaint, <i>Purdue Pharma L.P. et al. v. Amneal Pharmaceuticals, LLC</i> , No. 15-cv-01152 (D. Del. Dec. 15, 2015, ECF No. 1)
1021	Complaint, <i>Purdue Pharma L.P. et al. v. Amneal Pharmaceuticals, LLC</i> , No. 17-cv-01421 (D. Del. Oct. 10, 2017, ECF No. 1)
1022	Complaint, <i>Purdue Pharma L.P. et al. v. Amneal Pharmaceuticals, LLC</i> , No. 18-cv-00051 (D. Del. Jan. 3, 2018, ECF No. 1)
1023	Complaint, <i>Purdue Pharma L.P. et al. v. Kashiv Pharma, LLC</i> , No. 18-cv-00052 (D. Del. Jan. 3, 2018, ECF No. 1)
1024	U.S. Publication No. 2005/0031546 (“Bartholomaus”)
1025	U.S. Patent No. 6,488,963 (“McGinity”)
1026	U.S. Publication No. 2004/0170680 (“Oshlack 2”)
1027	U.S. Patent No. 5,273,758 (“Royce”)
1028	Antonio Moroni & Isaac Ghebre-Sellassie, <i>Application of Poly(Oxyethylene) Homopolymers in Sustained Release Solid Formulations</i> , 21(12) Drug Development & Industrial Pharmacy (1995), at 1411-28 (“Moroni”)
1029	Zezhi J. Shao <i>et al.</i> , <i>Effects of Formulation Variables and Post-compression Curing on Drug Release from a New Sustained-Release Matrix Material: Polyvinylacetate-Povidone</i> , 6(2) Pharmaceutical Development & Technology (2001), at 247-54 (“Shao”)
1030	Declaration of Hossein Omidian, Ph.D. (“Omidian Declaration”)
1031	<i>Curriculum Vitae</i> of Hossein Omidian, PhD
1032	U.S. Provisional Application No. 60/840,244
1033	U.S. Patent Application No. 14/729,660 (“the ‘660 Application”)
1034	Serial No. 14/729,660, Non-Final Office Action, Sept. 11, 2015
1035	Serial No. 14/729,660, Amendment, December 11, 2015
1036	Declaration of Richard O. Mannion Under C.F.R. § 1.132, Mar. 27, 2015
1037	Serial No. 14/729,660, Supplemental Amendment, Feb. 16, 2016

Patent Trial and Appeal Board
U.S. Patent and Trademark Office
February 28, 2018
Page 3


Exhibit #	Reference
1038	Serial No. 14/729,660, Final Rejection, Apr. 8, 2016
1039	Serial No. 14/729,660, Amendment After Final, June 3, 2016
1040	Serial No. 14/729,660, Notice of Allowance, June 29, 2016
1041	Mai <i>et al.</i> , <i>Effects of cold extrusion and heat treatment on the mechanical properties of polypropylene</i> , 15(86) <i>Matériaux et Constructions</i> (1982), at 99-106
1042	Hatim S. AlKhatib <i>et al.</i> , <i>Effects of Thermal Curing Conditions on Drug Release from Polyvinyl Acetate-Polyvinyl Pyrrolidone Matrices</i> , 11(1) <i>AAPS PharmSciTech</i> (Mar. 2010), at 253-66
1043	Patience Mpofo <i>et al.</i> , <i>Temperature influence of nonionic polyethylene oxide and anionic polyacrylamide on flocculation and dewatering behavior of kaolinite dispersions</i> , 271 <i>J. of Colloid & Interface Sci.</i> (Mar. 2004), at 145-56
1044	OxyContin, <i>Physician's Desk Reference</i> 2569-74 (53rd ed. 1999)
1045	Dow 2002 product catalog
1046	Dow 2004 product catalog
1047	Handbook of pharmaceutical excipients
1048	U.S. Pub. No. 2004/0037883 ("Zhou")
1049	A. Apicella <i>et al.</i> , <i>Poly(ethylene oxide) (PEO) and different molecular weight PEO blends monolithic devices for drug release</i> 14(2) <i>Biomaterials</i> (1993), at 83-90
1050	Omelczuk <i>et al.</i> , <i>The influence of thermal treatment on the physical-mechanical and dissolution properties of tablets containing poly(DL-lactic acid)</i> <i>Pharmaceutical Research</i> , Vol. 10, No. 4 (1993)
1051	U.S. Patent No. 5,639,476 ("Oshlack 3")
1052	Kurt H. Bauer <i>et al.</i> , <i>Coated Pharmaceutical Dosage Forms</i> , Scientific Publishers Stuttgart (1998), at 86-87
1053	Serial No. 13/726,324 Suppl. Prelim. Amendment, Jan. 23, 2013
1054	Decision, Institution of <i>Inter Partes</i> Review 37 C.F.R. § 42.108, <i>Amneal v. Purdue</i> , IPR2016-01027 (P.T.A.B. Nov. 9, 2016), Paper No. 13
1055	U.S. Patent No. 9,492,392 ("the '392 Patent")
1056	Final Written Decision, <i>Amneal v. Purdue</i> , IPR2016-01027 (P.T.A.B. Nov. 8, 2016), Paper No. 48
1057	Johannes Bartholomäus, PhD <i>et al.</i> , <i>New Abuse Deterrent Formulation (ADF) Technology for Immediate-Release Opioids</i> , <i>Abuse Deterrent Technology</i> , 13(8) <i>Drug Development & Delivery</i> (October 2013)
1058	Final Written Decision, <i>Amneal v. Purdue</i> , IPR2016-01028 (P.T.A.B. Nov. 8, 2016), Paper No. 47
1059	Intentionally omitted

Patent Trial and Appeal Board
U.S. Patent and Trademark Office
February 28, 2018
Page 4

Exhibit #	Reference
1060	<i>Physicochemical properties and mechanism of drug release from ethyl cellulose matrix tablets prepared by direct compression and hot-melt extrusion</i> , 269 International Journal of Pharmaceutics (2004) 269, 509-522, at 515, Table 1 (“Crowley”)
1061	U.S. Publication No. 2005/0233062 (“Hossainy”)
1062	U.S. Patent No. 5,160,743 (“Edgren”)
1063	US 2007/0190142 (“Breitenbach”)
1064	Orange Book on MS CONTIN
1065	Orange Book on ORAMORPH SR
1066	Orange Book on OPANA ER
1067	PDR MS CONTIN 2005
1068	PDR ORAMORPH SR 2005

Respectfully submitted,

LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP



Tedd W. Van Buskirk
Registration No. 46,282

TVB/dmf